Zacks Investment Research | Apr 04, 2019 09:03PM ET
ABIOMED, Inc.’s (NASDAQ:ABMD) flagship Impella has been proved to significantly increase cardiogenic shock survival and heart recovery in patients. Data exhibits that survival rates have increased from 51% to 67% since the device’s FDA Pre Market Approval for treating cardiogenic shock.
However, this latest development could not drive the Zacks Rank #2 (Buy) stock’s shares, which lost 0.5% to $282.87 at close.
Notably, this latest development fortifies the MedTech giant’s foothold in the U.S. cardiovascular devices market.
Impella in Focus
Impella, the world’s smallest heart pump, is ABIOMED’s flagship product line. The company’s Impella 2.5, Impella RP, Impella 5.0 and Automated Impella Controller deserve a mention in this regard.
Notably, the product has been driving the company’s top line since inception.
Management confirmed that ABIOMED is currently investing in the commercial distribution to prepare for the expansion of Impella CP, Impella Connect, Impella 5.5 and Impella RP.
Interestingly, ABIOMED’s new technology called Impella Connect has been launched at 36 U.S. hospitals in recent times.
In the last reported quarter, Impella heart pump revenues jumped 31% year over year.
Market Prospects
Per research by CDC, nearly 610,000 people die of heart diseases each year in the United States.
Statista validates that the U.S. cardiovascular devices market is expected to reach a worth of $15.7 billion by 2021.
Thus, the latest development has been a well-timed one for ABIOMED.
Price Performance
We believe positive developments such as these would drive the shares of ABIOMED which have declined 3.2% against the .
Varian Medical’s long-term earnings growth is projected at 8%.
Masimo’s long-term earnings are expected to grow 15.6%.
Penumbra’s long-term earnings growth rate is estimated at 20.9%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.